EVAX - CIK 0001828253
The table below shows Evaxion Biotech A/S's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $9.97M | $10.46M | $11.92M | $17.06M | $19.58M | $10.90M |
| SG&A | $6.79M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $7.62M |
| $10.35M |
| $8.21M |
| $6.25M |
| $5.67M |
| Operating income | - | - | - | - | - | - |
| Income tax | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - |
| EPS (diluted) | - | - | - | - | - | - |